Latest research on Ustekinumab

CNTO 1275 is the experimental name for the human immunosuppressive drug ustekinumab developed by the biotechnology company Centocor. It is a laboratory-manufactured, monoclonal antibody directed against interleukins IL-12 and IL-23 and presently undergoing clinical trials to determine its safety and effectiveness against the diseases Multiple Sclerosis, Psoriasis, and Psoriatic Arthritis.

Latest findings

The importance of this pathway in regulating pro-inflammatory effects seen in IBD is highlighted by the clinical improvement seen in patients with CD when treated with Ustekinumab, a monoclonal antibody directed against the p40 subunit shared by IL-12 and IL-23 [source, 2016]
Apart from anti-TNF therapies, another biologic treatment is Ustekinumab, which targets the shared p40 subunit of the proinflammatory cytokines IL-12 and IL-23 [7]. [source, 2016]
IL23 is a drug target for Ustekinumab, currently used as a treatment for psoriasis. [source, 2016]
Ustekinumab is a human monoclonal antibody against interleukin-12 and interleukin-23 that has primarily been used in the treatment of psoriasis. [source, 2016]
Ustekinumab has recently been used as an emerging biologic agent in the management of patients with CD.1 [source, 2016]
He was therefore switched from certolizumab pegol to Ustekinumab at 90 mg subcutaneously every 8 weeks; over the next several months, he achieved prolonged symptom remission off all steroids and acid suppression. [source, 2016]
His peri-stomal fistulae and ileitis were also well-controlled with Ustekinumab. [source, 2016]
Ustekinumab has shown promise in treatment of refractory, typically intestinal CD. [source, 2016]
The efficacy of Ustekinumab as first-line therapy for intestinal CD has been limited. [source, 2016]
To our knowledge, there are no prior reports on the successful use of Ustekinumab in esophageal CD. [source, 2016]